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of EQ-5D, the frequency of T2DM patients responding as having “some problem” 
and “extreme problem” was 4.6% and 1.6% for mobility, 7.9% and 1.4% for self-
care, 13.9% and 1.7% for usual activities, 27.5% and 1.1% for pain/discomfort, and 
26.6% and 1.3% for anxiety/depression, respectively. The mean VAS score (±SD) of 
patients was 70.4 ± 15.1. CONCLUSIONS: The rates of T2DM patients with “some 
problem” in pain/discomfort, and anxiety/depression were relatively high; rate with 
“extreme problem” for usual activities was also higher than other dimensions. The 
results of 5D were consistent with the low VAS score. These ﬁ ndings imply that there 
was a signiﬁ cant impact on the health status of T2DM patients with OADs therapy 
due to pain/discomfort, and anxiety/depression. It underscores the urgent need to 
adopt effective measures toward prevention and control of diabetes to improve 
patients’ quality of life.
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OBJECTIVES: The objective of this study was to elicit quality-adjusted life-year 
(QALY) weights for the different severity levels of diabetic retinopathy (DR) and to 
evaluate the adequacy of using certain health-related quality of life (HRQoL) instru-
ments for this purpose. METHODS: The study population comprises 151 patients 
with diabetes (type 1 and 2) that either attended the eye clinic at Linköping University 
Hospital or were registered at any of the two vision centrals in Östergötland County, 
Sweden. Participants were interviewed over the phone using time trade-off (TTO) 
questions, the EuroQol Health Questionnaire (EQ-5D), the Health Utilities Index 
Mark III (HUI-3) and the National Eye Institute Visual Function Questionnaire (NEI-
VFQ-25). The effect of other variables than DR on QALY weights was investigated 
using ANCOVA and the generic instruments were tested for correlation with NEI-
VFQ-25. RESULTS: The ranges of the QALY weights estimated with the three generic 
instruments were for no DR, BR, PDR, maculopathy and legal blindness 0.81–0.88, 
0.72–0.78, 0.75–0.82, 0.74–0.81 and 0.39–0.68 respectively. In general, the differ-
ences in QALY weights between the different severity levels were reduced when 
adjusted for clinical characteristics and co-morbidities. The difference in QALY 
weights between the patients with no DR and legal blindness was signiﬁ cant for all 
instruments. The correlations between the results from NEI-VFQ-25 and TTO, EQ-5D 
score, EQ-5D VAS and HUI-3 were 0.27, 0.31, 0.38 and 0.68 respectively. CONCLU-
SIONS: This study presents QALY weights for different severity levels of DR, which 
can be used in cost-effectiveness analyses of interventions directed to DR. Of the 
instruments we used, HUI-3 seems to be the most sensitive to changes in HRQoL due 
to progression of DR.
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OBJECTIVES: The QoL-AGHDA is the ﬁ rst true quality of life (QoL) measure for 
adult growth hormone deﬁ ciency and is widely used in clinical practice and trials. In 
the UK NICE advises that scores on the QoL-AGHDA should be used to guide treat-
ment selection. The scale has good psychometric properties and has been shown to 
be responsive to changes in disease severity. The objective of the study was to adapt 
the QoL-AGHDA for the Czech Republic, Poland, Serbia, Slovakia and Brazil. 
METHODS: The adaptation in each country required three stages: Translation, cogni-
tive debrieﬁ ng and a validation survey. The dual panel translation method was used 
to ensure the items were translated accurately and expressed in everyday language. 
Cognitive-debrieﬁ ng interviews with local patients assessed face and content validity. 
The validation survey tested the psychometric properties of the new scales and 
included the Nottingham Health Proﬁ le (NHP) as a comparator measure. RESULTS: 
Validation data are not available for Slovakia. Mean scores on the new versions of 
the QoL-AGHDA ranged from 6.2 to 11.8 (maximum possible = 25). Internal con-
sistency ranged from 0.89–0.91 and test-retest reliability from 0.88–0.93. QoL-
AGHDA scores were statistically signiﬁ cantly related to; perceived general health and 
level of fatigue in the Czech Republic, perceived physical activity and level of fatigue 
in Poland and Serbia and to perceived general health and rated QoL in Brazil. Across 
the countries mean correlations with NHP sections were (as expected) highest with 
energy level and emotional reactions (correlations 0.68–0.83) and lowest with sleep 
disturbance and pain (correlations 0.38–0.46). CONCLUSIONS: This study indicates 
that (with the exception of Slovakia which requires further validation) the new lan-
guage versions of the QoL-AGHDA meet the standards of the original UK version 
and the other 9 existing versions. The new adaptations represent valid and reliable 
tools for measuring QoL in international clinical trials.
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OBJECTIVES: Hypoglycaemia can be a side effect of glucose-lowering treatment in 
patients with type 2 diabetes (T2D) that may counterbalance the beneﬁ cial effects of 
diabetes control. PANORAMA is a large (n = 5156) pan-European cross-sectional 
survey (NCT00916513) of patients assessing patient reported outcomes and glycaemic 
control. This subgroup analysis compared rates of severe and non-severe hypoglycae-
mic events in patients taking different pharmacological treatment regimens. 
METHODS: Patients with T2D were randomly or consecutively selected from medical 
practices in eight countries. Patients were aged ≥40 years, with T2D diagnosed >1 
year and a clinic medical record available >1 year. All patients received dietary/exercise 
advice and most were also taking either oral antidiabetic drugs (OADs) and/or inject-
ables (insulin and/or GLP-1 receptor agonists). Patients included in this subgroup 
analysis had been taking the same pharmacological treatment regimen for ≥12 months. 
Patient-reported frequency of severe (symptomatic episodes requiring external assis-
tance) and non-severe hypoglycaemic episodes in the past year were examined. 
RESULTS: In this subgroup analysis 3106 patients were evaluated including: 1346 
taking only OADs without secretagogues; 1452 taking only OADs including secreta-
gogues (sulphonylurea/glinides) and 308 on insulin alone. The percentages of patients 
experiencing >1 non-severe hypoglycaemic episode in each treatment group were: 
8.9% for patients taking OADs without secretagogues; 17.5% for patients taking 
OADs including secretagogues and 47.4% for patients using insulin alone. The dif-
ferences between these three treatment categories (pair-wise comparisons) were highly 
signiﬁ cant (P < 0.001). The percentage of patients reporting ≥1 severe hypoglycaemic 
episode was greater for OADs including secretagogues versus no secretagogues (3.0% 
versus 1.3%; P = 0.011) and for insulin alone versus OADs including secretagogues 
(13.7% versus 3.0%; P < 0.001). CONCLUSIONS: Among patients with T2D on 
glucose-lowering medication, rates of non-severe and severe hypoglycaemic episodes 
were lowest amongst patients treated with OADs not including secretagogues and 
highest among patients treated with insulin alone.
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OBJECTIVES: Understanding the perspectives of Type 2 Diabetes (T2D) patients on 
hypoglycemia is important, in order to understand the burden of the disease and its 
treatment, and to develop improved outcome measures. The goal of this project was 
to identify key hypoglycemia-related concepts among T2D patients using qualitative 
interviews. METHODS: Participants were 19 T2D patients who were prescribed: 1) 
an oral anti-diabetic (OAD) and had been diagnosed with T2D in the past 3 years (n 
= 11); 2) a sulfonylurea (SU) or thiazolidinedione (TZD) that caused weight gain, 
following the failure of an OAD in the last year (n = 5); or 3) an incretin mimetic that 
caused weight loss, following the failure of an OAD in the last year (n = 3). One-hour 
in-person interviews were conducted using a semi-structured interview guide. Inter-
views were coded using ATLAS.ti software and code frequency was used to identify 
key experiences. RESULTS: Patients were 54.4 years of age on average and 63% were 
female. Tremor, sweating, and dizziness were the most commonly noted symptoms of 
hypoglycemia; all ﬁ ve of the patients on an SU or TZD reported experiencing tremor. 
Patients reported concerns about rare, severe events, such as passing out. Patients 
generally did not report that their lives were substantially impacted by hypoglycemia, 
but completing compensatory behaviors to prevent hypoglycemia emerged as an 
important theme (keeping glucotabs in multiple locations, eating large meals). CON-
CLUSIONS: Hypoglycemia has a negative impact on patients with T2D. Many report 
experiencing hypoglycemia symptoms, and, although T2D patients do not often report 
anxiety about hypoglycemia, several reported concerns about the consequences of 
severe events. Patients also engage in compensatory behaviors, which suggests that 
avoiding hypoglycemia is important. Further reﬁ nement of the concepts associated 
with the patient’s experience of hypoglycemia may yield new PRO instruments that 
can be implemented in clinical trials with T2D patients.
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OBJECTIVES: Maintaining a healthy weight is important in the management of 
T2DM. We investigated the relationship between weight and patient concerns in rela-
tion to overall health-related well-being and function among those with T2DM. 
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METHODS: This cross-sectional study was conducted in the UK, France (FR), and 
Germany (DE), with data collected via a representative European online volunteer/
opt-in panel (called “MRops”). A 34-minute survey was ﬁ elded to 500 subjects with 
T2DM who were currently receiving pharmacotherapy in each country (n = 1500) 
from December 2007 to January 2008. Survey items asked about weight, concerns 
about weight and health, and health-related well-being and function as assessed by 
the SF-12® Health Survey. RESULTS: Based on self-reported height and weight, 85% 
(UK), 71% (FR), and 86% (DE) were overweight or obese. Weight was noted as the 
most important current health concern by 19% (UK), 19% (FR), and 21% (DE). Not 
all respondents (88% (UK), 79% (FR), 82% (DE)) indicated a desire to lose weight. 
More subjects with T2DM in DE were “very much” distressed (27%) by their weight 
than subjects in UK and FR (both 18%). However, the percentage who were “very 
much” worried about their health because of their weight (UK [20%], FR [14%], DE 
[21%]) and “very much” embarrassed by their weight (UK [12%] FR [16%] DE 
[11%]) was similar across countries. Health-related well-being and function, as 
assessed by the SF-12®, was worse across all domains in those with higher body mass 
index (BMI) and those with greater weight-related distress, worry, and embarrass-
ment. CONCLUSIONS: Results indicate that elevated BMI and perceptions about 
weight affect health-related well-being and function as assessed by the SF-12®. Thera-
peutic options that help people with T2DM to lose weight may have a positive impact 
on patient lives.
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BACKGROUND: Health-related quality of life (HRQoL) is a multidimensional 
concept that provides insight regarding the impact of a disease from the patient’s 
perspective and yield an important health outcome to evaluate treatment interventions 
and quality of health care. OBJECTIVES: The goal of this study is to reveal HRQoL 
of type 2 diabetes mellitus (T2DM) patients treated in the Brazilian private health care 
system. METHODS: A generic instrument to assess health status (EuroQol—EQ-5D), 
commonly used in diabetic patients worldwide, was applied in 383 outpatients with 
T2DM from ﬁ ve cities (Fortaleza, Porto Alegre, Rio de Janeiro, Ribeirão Preto e São 
Paulo). Euroqol uses ﬁ ve dimensions to describe HRQoL states (mobility, self-care, 
usual activities, pain/discomfort, anxiety/depression) and a visual analogue scale (VAS) 
recorded by the patient and was measured during only one time during the visit to 
the physician. RESULTS: The group was composed of 201 women and 182 men, aged 
60.5 ± 9.6 years, mean BMI 29.1 kg/m2 and mean duration of diabetes of 12.2 ± 8.75 
years. For the entire group, mean EQ VAS score was 75.15 ± 16.72, 24.5% reported 
some problems with mobility, 4.2% with self-care, 17.5% problems in their usual 
activities, 44.9% any pain/discomfort and 45.2% anxiety/depression. Mean EQ VAS 
score decreased as diabetes duration increased (78.19 < 9 years vs. 73.26 > 19 years 
of disease; P = 0.05). The patients without micro and macrovascular complications 
(41.5%) had a higher VAS compared to those with these complications (18%) (VAS 
77.5 vs. 70.19; P = 0.002). Retinopathy (VAS = 68.13) and heart failure (VAS = 67.05) 
were conditions associated with lower EQ VAS scores. Regarding the type of treat-
ment, VAS was lower in insulin-treated patients compared to oral agents users (VAS 
= 76.59 vs. 71.54; P = 0,00004). CONCLUSIONS: A longer duration of diabetes, the 
presence of chronic complications and the use of insulin showed a negative impact on 
T2DM patient’s HRQoL.
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OBJECTIVES: Aim of this study was to evaluate the quality of medical treatment of 
diabetes patients and its trends in the Czech Republic and to compare the ﬁ ndings 
with the international research. Based on IDF prevalence of diabetes was 9,7% in 
2007 and is expected to rise to 11,7% in 2025. METHODS: Data were extracted 
from Czech cross-sectional studies from 2002 and 2007 and from European-based 
studies. Follow-up of short term parameters of quality of health care (HbA1c, BMI, 
blood pressure, lipids, treatment algorithms) which help to predict long-term incidence 
of complications. Frequency of microvascular and macrovascular complications was 
also assessed and the data were compared to statistics of the Czech Institute for Health 
Information and Statistics. RESULTS: Concerning short-term parameters there is wide 
variation accross European countries. We have not found signiﬁ cant differences 
between CR and selected European countries although there is insufﬁ cient evidence 
in revealing end-point values, e.g. HbA1c (7,7% in CR vs. 7,8% in Great Britain), 
BMI (29,9 in CR vs. 28,7 CODE-2 study) and reaching of target HbA1c values 
(36–42% in CR vs. 36% in CODE-2). 74% of Czech patients compared with 50% 
European patients are treated with metformin. Percentage of patients using antihyper-
tention drugs (83%) and hypolipidemics (63%) is similar in CR and the European 
average. The diabetic patients are reaching the tagret therapeutic values only in minor-
ity of cases (31% in systolic blood pressure, 27% in total cholesterol and in 36% of 
HbA1c). There is high prevalence of diabetic macrovascular and microvascular com-
plications (CHD = 49%, stroke = 9,3%, nephropathy = 28,3%, retinopathy = 25%, 
diabetic foot = 4,6%). CONCLUSIONS: This comparative analysis is the ﬁ rst example 
of systematic evaluation of the quality of health care concerning diabetes patients in 
CR. The future objective is to set proper quality indicators and follow them on con-
tinuous basis. 
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OBJECTIVES: This study aimed to investigate in people with type 2 diabetes (T2D) 
the relative willingness-to-pay (WTP) for different diabetes drug therapies based on 
outcomes of clinical trials with liraglutide. METHODS: WTP for diabetes drug 
therapy of people with T2D was assessed by combining results from a meta-analysis 
of liraglutide compared with other diabetes drug therapies in the liraglutide clinical 
development program (LEAD) and a survey on WTP for important aspects of diabetes 
medication in people with T2D. a meta-analysis of six randomised trials with 3967 
subjects in the LEAD program compared efﬁ cacy and safety of liraglutide, a once-daily 
human glucagon-like peptide-1 (GLP-1) analogue, vs. rosiglitazone, glimepiride, 
insulin glargine, and exenatide. The WTP survey had 461 participants with T2D from 
Sweden and used a discrete choice experiment methodology to evaluate convenience 
and clinical effects of treatments in T2D. Results were converted from SEK to c (10.14 
SEK/c). RESULTS: Combining meta-analysis and WTP results revealed that people 
with T2D preferred liraglutide to all comparators. They were willing to pay an extra 
c2.49/day for liraglutide 1.2 mg compared with rosiglitazone, c1.82/day compared to 
glimepiride, c3.17/day compared to insulin glargine, and c0.74/day compared to 
exenatide. For the comparisons with rosiglitazone, glimepiride and insulin glargine, 
the largest component was based on the additional weight improvements with lira-
glutide. Compared to exenatide, the largest component of preference was administra-
tion of the drug. CONCLUSIONS: WTP for liraglutide by people with T2D was 
noticeably higher compared to other standard therapies based on the clinical results 
from the meta-analysis. Primary drivers were weight decrease (compared to rosigli-
tazone, glimepiride and insulin glargine) and administration (compared to exenatide). 
In total, people were willing to pay up to c3.17/day more to use liraglutide 1.2 mg 
rather than use other glucose lowering treatments.
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OBJECTIVES: The duration of treatment with NPH, as a ﬁ rst insulin medication in 
type 2 diabetes is reported to be shorter than that of insulin glargine, with comparisons 
of glargine and insulin detemir inconsistent. We investigated whether differences 
remained after adjustment for potential confounders, including baseline HbA1c, and 
which factors are associated with longer duration of use of ﬁ rst insulin. METHODS: 
People on two or three oral glucose-lowering agents (OGLA) with poor glycaemic 
control who started long-term insulin treatment (2000–2007) were grouped by insulin 
type, NPH, glargine or detemir, and followed until a prescription for a different insulin 
or a GLP-1 mimetic. Time to treatment change was compared between groups in a 
Cox model adjusting for baseline characteristics: HbA1c, age, sex, year, time from 
diagnosis, concomitant OGLA, glomerular ﬁ ltration rate, cardio- and micro-vascular 
medical history and cardiovascular risk factors. The association of this duration with 
baseline characteristics and mean treatment HbA1c was investigated by univariate 
analyses. All data came from THIN database of electronic UK primary care records. 
RESULTS: The analysis included 1044 people started on glargine therapy; 187 on 
detemir and 453 on NPH. Compared to glargine the adjusted hazard ratios for time 
to treatment change were 1.78 (95%CI 1.43, 2.20) for detemir and 1.52 (1.29, 1.80) 
for NPH. Lower mean HbA1c with any insulin type was associated with longer time 
to change of regimen (Spearman rank correlation coefﬁ cient −0.30, P < 0.001). No 
concomitant OGLA use, increasing age and time from diagnosis, decreasing BMI and 
baseline HbA1c and heart failure were also associated with longer ﬁ rst insulin duration. 
CONCLUSIONS: People who commenced insulin treatment with glargine remained 
on their initial insulin for longer than those who initiated detemir or NPH after adjust-
ment for potential confounders. Better glycaemic control resulted in a longer time to 
change of insulin.
